NYSE:DVA - DaVita Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $124.50
Forecasted Upside: 1.40 %
Number of Analysts: 4
Breakdown:
1 Sell Ratings
2 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$122.78 As of 06/16/2021 05:43 PM ET

▼ -0.86 (-0.70%)

1 month | 3 months | 12 months

Get New DaVita Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DVA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$124.50

▲ +1.40% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for DaVita in the last 3 months. The average price target is $124.50, with a high forecast of $150.00 and a low forecast of $100.00. The average price target represents a 1.40% upside from the last price of $122.78.

Hold

The current consensus among 4 polled investment analysts is to hold stock in DaVita. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
2 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
2 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
2 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
2 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/1/2021	Bank of America	Reiterated Rating	Neutral ➝ Underperform	$127.00 ➝ $118.00	High	i Rating by Kevin Fischbeck at Bank of America Co.
3/26/2021	Bank of America	Downgrade	Neutral ➝ Underperform	$127.00 ➝ $118.00	Medium	i
1/13/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$105.00 ➝ $150.00	High	i
1/5/2021	Truist	Boost Price Target		$100.00 ➝ $130.00	N/A	i
1/5/2021	Bank of America	Downgrade	Buy ➝ Neutral	$127.00	N/A	i
9/15/2020	Raymond James	Reiterated Rating	Hold		Medium	i
7/31/2020	SunTrust Banks	Boost Price Target	Hold	$90.00 ➝ $100.00	Low	i
5/6/2020	SunTrust Banks	Boost Price Target	Hold	$82.00 ➝ $90.00	High	i
4/20/2020	Royal Bank of Canada	Reiterated Rating	Hold	$75.00	Low	i
4/13/2020	SunTrust Banks	Lower Price Target	Hold	$90.00 ➝ $82.00	Medium	i
2/11/2020	SunTrust Banks	Set Price Target		$90.00	High	i
1/24/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy		High	i
1/3/2020	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$60.00	Low	i
12/20/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	$65.00 ➝ $75.00	Low	i
12/18/2019	SunTrust Banks	Boost Price Target	Hold	$72.00 ➝ $80.00	Medium	i
11/12/2019	Sanford C. Bernstein	Initiated Coverage	Market Perform		Low	i
11/7/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium	i
11/6/2019	SunTrust Banks	Boost Price Target	Hold	$72.00	High	i
10/25/2019	Wolfe Research	Downgrade	Outperform ➝ Market Perform	$57.00	Low	i
9/11/2019	William Blair	Downgrade	Outperform ➝ Market Perform		Medium	i Rating by Matt Larew at William Blair
9/11/2019	SunTrust Banks	Reiterated Rating	Positive ➝ Hold	$68.00	Medium	i
8/22/2019	UBS Group	Lower Price Target	Neutral	$61.00 ➝ $60.00	Low	i
7/26/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$70.00 ➝ $65.00	Medium	i
6/20/2019	William Blair	Reiterated Rating	Buy		Medium	i Rating by Matt Larew at William Blair
5/9/2019	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$68.00 ➝ $66.00	Medium	i
2/20/2019	SunTrust Banks	Reiterated Rating	Neutral ➝ Hold		Low	i
2/15/2019	Robert W. Baird	Lower Price Target	Outperform	$90.00 ➝ $70.00	Low	i
1/9/2019	Royal Bank of Canada	Reiterated Rating	Hold	$65.00	Low	i
1/8/2019	UBS Group	Upgrade	Sell ➝ Neutral	$64.00 ➝ $59.00	Medium	i
1/3/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$60.00	Medium	i
12/14/2018	Barclays	Initiated Coverage	Overweight ➝ Overweight	$70.00	High	i
12/2/2018	Raymond James	Downgrade	Outperform ➝ Market Perform	$63.44	Low	i
11/28/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$70.00	High	i
11/15/2018	UBS Group	Initiated Coverage	Sell ➝ Sell	$64.00	Medium	i
11/8/2018	Royal Bank of Canada	Boost Price Target	Sector Perform ➝ Sector Perform	$70.00 ➝ $78.00	High	i
11/8/2018	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		N/A	i
9/13/2018	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral		High	i
6/6/2018	William Blair	Reiterated Rating	Buy		Medium	i Rating by Matt Larew at William Blair
2/14/2018	SunTrust Banks	Reiterated Rating	Hold	$80.00	Medium	i Rating by David S Macdonald at SunTrust Banks, Inc.
2/13/2018	Robert W. Baird	Set Price Target	Buy	$97.00	High	i Rating by Whit Mayo at Robert W. Baird
1/12/2018	Robert W. Baird	Reiterated Rating	Buy	$82.00 ➝ $95.00	Low	i Rating by Whit Mayo at Robert W. Baird
1/11/2018	Bank of America	Reiterated Rating	Buy	$85.00 ➝ $92.00	High	i
1/4/2018	Bank of America	Upgrade	Neutral ➝ Buy	$75.00 ➝ $85.00	High	i
12/21/2017	SunTrust Banks	Set Price Target	Hold	$75.00	Low	i Rating by David S Macdonald at SunTrust Banks, Inc.
12/12/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$63.00 ➝ $82.00	Low	i
12/11/2017	Citigroup	Upgrade	Neutral ➝ Buy	$67.71 ➝ $82.00	Medium	i Rating by Patrick Wood at Citigroup Inc.
12/7/2017	JPMorgan Chase & Co.	Boost Price Target	Outperform ➝ Strong-Buy	$4.90 ➝ $84.00	Low	i
12/7/2017	SunTrust Banks	Set Price Target	Sell ➝ Hold	$70.00	High	i Rating by David S Macdonald at SunTrust Banks, Inc.
12/7/2017	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$65.00 ➝ $84.00	High	i
12/6/2017	KeyCorp	Reiterated Rating	Hold		Low	i Rating by Jason Gurda at KeyCorp
11/13/2017	KeyCorp	Reiterated Rating	Hold		N/A	i Rating by Jason Gurda at KeyCorp
11/10/2017	Robert W. Baird	Reiterated Rating	Hold	$63.00	N/A	i
11/8/2017	Bank of America	Lower Price Target	Neutral	$75.00 ➝ $66.00	N/A	i
11/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$64.00 ➝ $60.00	N/A	i
10/23/2017	Wolfe Research	Upgrade	Market Perform ➝ Outperform		N/A	i
10/15/2017	SunTrust Banks	Set Price Target	Hold	$57.00	N/A	i Rating by David S Macdonald at SunTrust Banks, Inc.
10/10/2017	KeyCorp	Reiterated Rating	Hold		N/A	i Rating by Jason Gurda at KeyCorp
10/9/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		N/A	i
9/6/2017	Royal Bank of Canada	Reiterated Rating	Hold	$64.00	Low	i
8/3/2017	Jefferies Financial Group	Reiterated Rating	Hold	$70.00	Medium	i Rating by Chris Cooper at Jefferies Financial Group Inc.
6/26/2017	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$64.89 ➝ $70.00	Low	i Rating by Chris Cooper at Jefferies Financial Group Inc.
5/26/2017	Jefferies Financial Group	Set Price Target	Buy	$70.00	N/A	i Rating by Chris Cooper at Jefferies Financial Group Inc.
5/25/2017	The Goldman Sachs Group	Reiterated Rating	Sell	$62.00	High	i
2/17/2017	Royal Bank of Canada	Reiterated Rating	Hold	$62.00	N/A	i
12/13/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$68.00 ➝ $69.00	N/A	i
11/21/2016	Bank of America	Reiterated Rating	Hold	$68.00	N/A	i
11/19/2016	Jefferies Financial Group	Reiterated Rating	Buy	$86.00 ➝ $70.00	N/A	i
11/1/2016	Wells Fargo & Company	Reiterated Rating	Outperform		N/A	i Rating by Gary Lieberman at Wells Fargo & Company
10/13/2016	SunTrust Banks	Set Price Target	Hold	$66.00	N/A	i Rating by David S Macdonald at SunTrust Banks, Inc.
9/20/2016	Raymond James	Upgrade	Market Perform ➝ Outperform	$75.00	N/A	i
9/6/2016	Bank of America	Downgrade	Buy ➝ Neutral	$70.00	N/A	i
9/6/2016	Citigroup	Initiated Coverage	Neutral	$71.00	N/A	i
8/9/2016	JPMorgan Chase & Co.	Boost Price Target	Neutral	$74.00 ➝ $75.00	N/A	i

(Data available from 6/16/2016 forward)

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Today's Range

Now: $122.78

$122.32

$124.01

50 Day Range

MA: $118.64

$106.86

$127.98

52 Week Range

Now: $122.78

$75.30

$129.59

Volume

567,795 shs

Average Volume

708,742 shs

Market Capitalization

$13.04 billion

P/E Ratio

18.92

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of DaVita?

The following sell-side analysts have issued reports on DaVita in the last twelve months: Bank of America Co., Deutsche Bank Aktiengesellschaft, Raymond James, SunTrust Banks, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for DVA.

What is the current price target for DaVita?

4 Wall Street analysts have set twelve-month price targets for DaVita in the last year. Their average twelve-month price target is $124.50, suggesting a possible upside of 1.4%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting DVA will reach $150.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $100.00 for DaVita in the next year.
View the latest price targets for DVA.

What is the current consensus analyst rating for DaVita?

DaVita currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DVA, but not buy more shares or sell existing shares.
View the latest ratings for DVA.

What other companies compete with DaVita?

Other companies that are similar to DaVita include Laboratory Co. of America, Quest Diagnostics, Amedisys, Chemed, LHC Group, R1 RCM, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact DaVita's investor relations team?

DaVita's physical mailing address is 2000 16TH STREET, DENVER CO, 80202. The company's listed phone number is 720-631-2100 and its investor relations email address is [email protected] The official website for DaVita is www.davita.com.